Greenblatt is a Professor Emeritus in the UC San Francisco Department of Clinical Pharmacy, where she chaired the UCSF School of Pharmacy Faculty Council. When she first began at UCSF, her primary appointment was in the UCSF School of Medicine. She was full-time faculty at the time of her selection as the FRL recipient in Clinical Science.
The event took place Thursday, Oct. 5, 2017 in Cole Hall on the Parnassus campus. The event was live simulcast and is available for viewing for one year.
Greenblatt presented on her 31-year career at UCSF by focusing on her research on the human immunodeficiency virus (HIV), specifically women at risk of and/or living with HIV. The lecture was entitled, “A Career in HIV Research and the Meaning of Community.”
The FRL series began in 1957 with a basic science award and in the following years grew to include clinical and translational science awards. Clinical science focuses on bedside research, or faculty who study human subjects in person through surveys, case series, or case-control studies. The FRL awards are given to three separate, distinguished faculty members each year. After UCSF faculty submit nominations, the Senate’s COR makes the final decisions.
“It is a tremendous honor to be selected by my colleagues at UCSF,” Greenblatt said. “UCSF is an outstanding research institution and the faculty have a record of excellence, so to be nominated and selected by my colleagues is very meaningful.”
Greenblatt’s research has found distinct phenotypes of HIV disease in women that led to improved clinical trials methods and information on experimental treatment outcomes for women and racial minorities. Specifically, Greenblatt’s HIV research studies include: susceptibility to HIV, the effects of ovarian aging and menopause on HIV, and anti-retroviral pharmacology.
Born in Wisconsin, Greenblatt grew up mostly in Maryland. In high school, Greenblatt completed her first bench research project on phospholipids cycads. She attended Case Western Reserve University (CWRU) in Cleveland, receiving a Bachelor of Science in chemistry and psychology and her MD. At CWRU, she completed bench research in radiation biology, field research on anemia in Navajo children in Chinle, Arizona, and field research on schistosomiasis in Kenya. The AIDS epidemic was first identified in 1981, the same year Greenblatt graduated from medical school.
Following CWRU, Greenblatt attended University of Washington for an Infectious Diseases Fellowship, which allowed her to return to Kenya to do bench and field research on genital ulcer disease (GUD) and HIV.
“In Kenya AIDS cases were hard to ignore, even though formally, Kenya had not yet recognized the epidemic,” Greenblatt said. “So working in AIDS, and then HIV, when the virus was identified, seemed like a responsibility.”
Greenblatt came to UCSF as part of the Robert Wood Johnson Clinical Scholars Program in 1986, which funded up to three years of graduate-level, or post residency research. The program places individuals at multiple sites; Greenblatt was assigned to UCSF, one of her top three choices. During that time, Greenblatt did behavioral and field research on teen risk, disability, alternative treatments, and accuracy of medical records.
“After completing my fellowship and residency at UCSF, what kept me here was the people,” Greenblatt said.
“I was particularly interested in HIV research in women because initially they were not studied and services were not optimal,” Greenblatt said. “Also, HIV in the U.S. is becoming focused on the poor and marginalized. It seems important to understand that and address what is not known and to provide the best care we can.”Connie Wofsy Women’s HIV Study (CWWHS), which is a regional cohort research study that contributes information to the Women’s Interagency HIV Study (WIHS). WIHS began in 1993, and is the largest HIV study of women with HIV, and is an ongoing nine-site study of many aspects of HIV among women in the US.
For the past few years, Greenblatt has collaborated with a team of three other researchers on the CWWHS leadership cohort, including: Project Director Jennifer Cohen, MPA; Principal Investigator Bradley Aouizerat, PhD; and Principal Investigator Phyllis Tien, MD, MSc. A few findings that have come from WIHS research include: development of standard approaches adequate for prevention of cervical cancer, HIV suppression reduces the risk of cervical epithelial neoplasia, and HIV positive and negative participants show peripheral vascular disease at an early age. Greenblatt has collaborated with twelve other UCSF faculty through the WIHS study.
Now as an Emeritus Professor, Greenblatt’s schedule has changed, but she still serves on the CWWHS leadership cohort as a PI. They hold a monthly video call and at the beginning of the year, the leadership cohort will change.
“We bring diversity within this research cohort by having professionals from different schools and we recruit researchers from different areas outside of HIV, like lung and heart,” Greenblatt said.
Beyond her work in research and the School of Pharmacy, Greenblatt’s career has also included service on the Academic Senate since 1993, including:
- Divisional Chair and Vice Chair, UCSF Academic Senate 2015-2017 (and Chair and Vice Chair, Senate’s Executive Council)
- The Committee on Academic Planning and Budget (APB): member
- The Committee on Committees (COC): member, Chair, and Vice Chair
- The Committee on Equal Opportunity (EQOP): member
- The Committee on Privilege and Tenure (P&T): member and Chair
- The Committee on Sustainability (SUST-A): Chair
- The School of Pharmacy Faculty Council (SOP FC): member, Chair, and Vice Chair
“Serving as Chair of the Senate gave me a wonderful view of UCSF and how it relates to the University of California,” Greenblatt said. “I am very proud of UCSF, its faculty, leadership, staff, and students. It is a great institution. The Senate attracts people who care about the academic community and are service oriented, which is inspiring.”
Outside of UCSF, Greenblatt enjoys spending time with family, sewing, and quilting.
The next FRL events will take place on Dec. 7 for translational science research and on March 8 for basic science research.
This article was originally published by the UCSF Academic Senate.